Plasma Cell DNA Content and Proliferation, Bone Marrow
Use
This test is useful for establishing a diagnosis of plasma cell proliferative disorders, including multiple myeloma and other related conditions. It provides prognostic information for newly diagnosed multiple myeloma, assesses the response to therapy, and detects disease relapse and progression in treated patients. It determines the plasma cell DNA content and proliferation to provide valuable insights into the disease's clinical progression and aggressiveness.
Special Instructions
Not provided.
Limitations
Plasma cell proliferation may not be determined if fewer than 300 abnormal plasma cell events or when multiple aneuploid cell populations are present. Additionally, the test results rely on accurate specimen processing, and the aging of the specimen could affect the antigen loss, affecting the percentage of clonal plasma cells.
New York Approved
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
Monotypic Plasma Cells
Cell Type
LOINC Codes
- 93363-0 - PC DNA content + prolif Pnl Mar FC
- 93362-2 - Monotypic plasma cells Mar FC
- 93021-4 - PC.abnormal/Cells NFr Mar FC
- 93361-4 - Mono PC in S Phs NFr Mar FC
- 93360-6 - Monotypic PC DNA index Mar FC-Rto
- 93359-8 - Monotypic PC DNA ploidy Mar FC
- 93358-0 - Polyclonal PCs/Cells NFr Mar FC
- 93020-6 - Polyclonal PCs/Total PCs NFr Mar FC
- 50398-7 - Narrative diagnostic report-Imp
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
4 mL
Minimum Volume
2 mL
Container
Yellow top (ACD solution A or B)
Collection Instructions
Ensure marrow specimen is from a 'redirect' aspirate. Acceptable alternative: Lavender top (EDTA) or green top (sodium heparin).
Causes for Rejection
Gross hemolysis, fully clotted specimens will be rejected.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 days |